Gevorg Tamamyan: The most important thing about OncoDaily

Gevorg Tamamyan shared a post on LinkedIn:

”A few days ago, I discovered something important about OncoDaily and our work. It’s well-known that bad news tends to attract more public attention, which is why many news channels focus heavily on negative stories. However, during a team discussion, we realized that despite our focus on positive news, our engagement rates are rising. This made us wonder: have people got tired of negative news? Do they look for more positive stories? Whatever the reason, we are committed to bringing positive news to people’s lives while staying true to current scientific evidence and realities.

We established OncoDaily in May 2023, and in just one year, we have made significant progress. Starting from scratch, OncoDaily has quickly become one of the leading oncology media platforms globally. Here are some of our major accomplishments:

1. We began with three people—the two co-founders and one team member. Now, we have nearly 40 staff members and featuring thousands contributors worldwide.
2. We provide around 100 news stories daily from all over the world. To the best of my knowledge, we are unique in the medical field for this level of intensive daily coverage.
3. On LinkedIn, our engagement metrics surpass those of many major global news channels, indicating that people love our content (Image 1).
4. On X, OncoDaily has been leading the #oncology hashtag for more than half a year, according to Symplur (Image 2).
5. The OncoDaily Party and Yvonne Awards Ceremony during ASCO was a unique event, attracting around 1,200 registrants and attendees in Chicago. It was a great networking experience for many. Read more about it.
6. A few days ago, a friend from one of the leading hospitals in the United States messaged me, saying, ‘Walked by the oncology clinic today… Chief is reading OncoDaily magazine :)’ Our first printed magazine issue was distributed in 3,000 copies worldwide (you may access digital version here).
7. On YouTube, our subscribers grew from around 200 to 16,000 (~80 times) in the last month.
8. We launched the OncoDaily Medical Journal, a peer-reviewed scientific journal that is poised to become a major scientific publication.
9. We hosted the 1st Global Summit on War and Cancer with the Institute of Cancer and Crisis. The Manifesto will be published in The Lancet in the coming days.
10. We hosted the 1st Global OncoThon, which was a great success. We will provide updates on this event soon.

This has been a huge team effort (THE BEST TEAM), and I am confident that the best is yet to come!”

Source: Gevorg Tamamyan/LinkedIn

Gevorg Tamamyan is the Editor-in-chief of OncoDaily, President-Elect of SIOP Asia Continental Branch and Pediatric Oncology East and Mediterranean (POEM) Group, and the CEO of the Immune Oncology Research Institute (IMMONC). He is the Chairman and Professor of the department of Haematology and Pediatric Oncology at Yerevan State Medical University.

He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.